a(CHEBI:rosiglitazone) decreases path(MESH:"Diabetes Mellitus, Type 2")

View Subject View Object

PubMed:21718217

The synthetic TZD PPAR-g agonists are widely prescribed for the treatment of type 2 diabetes mellitus, and have also been shown to be efficacious in a number of CNS disease models [21]. Currently, two TZD agonists, Actos (pioglitazone) and Avandia (rosiglitazone), are FDA approved for the treatment of diabetes.

Related Edges 3

• a(CHEBI:pioglitazone) increases act(p(HGNC:PPARG))
• a(CHEBI:pioglitazone) decreases path(MESH:"Diabetes Mellitus, Type 2")
• a(CHEBI:rosiglitazone) increases act(p(HGNC:PPARG))

Confidence

High

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.

---